NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Thanks for your opinion about the regulators.

I agree that the regulators are crucial. In my opinion, the FDA and NIH are quite significant and NIH support for Dr. Liau’s work is noteworthy. The NIH has supported Liau’s work for 20 consecutive years.




https://nwbio.com/wp-content/uploads/jamaoncology_liau_2022_oi_220066_1668698380.80695.pdf

September 14, 2022 Update of NIH NCI Funding of Dr. Liau

https://connect.uclahealth.org/2022/09/14/brain-cancer-discovery-clinical-trials/

9/14/2022
In a trial now underway, a dendritic cell vaccine is made from a participant's own tumor tissue and combined with an anti-PD1 immune checkpoint inhibitor to counter resistance when either treatment is used alone. The checkpoint drugs work by blocking the proteins that stop the immune system from attacking cancer cells.

"What I'm excited about is that we're seeing a growing number of long-term survivors in our patients treated with immunotherapy combinations," Dr. Liau says. "We're seeing some patients with certain combination immunotherapies that are living for many more years than would be expected. Currently, we're trying to find out what combination works best and for which patients."

The NIH is largely responsible for the development of the DCVax platform technology as they have always supported and funded Liau’s work. The 20 consecutive years of NIH funding of Dr. Liau have played a direct and crucial role in DCVax. Together with Merck, NIH is funding the DCVax doses going into arms TODAY in a study investigating its efficacy in combo with Keytruda.

https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/

https://www.bentley.edu/news/nih-funded-research-related-every-new-cancer-drug-approved-2010-2016

https://newsroom.ucla.edu/releases/nih-grant-lab-gene-cell-therapies


https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter